Keywords
obesity - cesarean - negative pressure wound therapy - wound infection
Cesarean delivery is the most commonly performed surgical procedure in the United
States. Of the approximately 3.9 million births in the United States in 2013, more
than 1.28 million (32.7%) occurred via cesarean delivery.[1] About 2 to 7% of cesarean deliveries resulted in a surgical site occurrence (SSO)
leading to prolonged wound healing and postoperative pain, increased rates of secondary
infection and rehospitalization, decreased patient satisfaction, and increased costs
of medical care.[2]
[3] Maternal obesity (BMI ≥ 30 kg/m2) at the time of cesarean delivery is a key factor impacting postcesarean incisional
morbidity.[4]
[5] Several studies show that obese women who undergo cesarean delivery have higher
rates of wound infection, seemingly independent of other known risk factors (e.g.,
diabetes and intrapartum intrauterine infection).[3]
[5]
Although a recent meta-analysis[6]
[7] and prior randomized controlled trials (RCTs)[7]
[8]
[9]
[10] of pregnant women with a range of BMIs suggest that closure with sutures is optimal
to closure with staples, there are scant data regarding whether negative pressure
over a closed incision might prevent postcesarean wound complications. In an RCT of
high-risk lower extremity trauma patients, use of closed-incision negative-pressure
therapy (ciNPT) showed decreased rates of postoperative infection and wound dehiscence.[11] In an RCT of 150 obese cardiac surgery patients, applying ciNPT to sternotomy incisions
significantly reduced postoperative wound infections as compared with standard-of-care
(SOC) dressings.[12]
Objective
The primary objective of this RCT was to compare short-term clinical outcomes among
obese pregnant women undergoing cesarean delivery who received ciNPT or a SOC dressing.
Study Design
We performed a single-center, postmarketing RCT at Duke University Medical Center
comparing ciNPT (PREVENA Incision Management System, KCI, an Acelity Company, San
Antonio, TX), to SOC dressing. Duke Institutional Review Board approval was obtained,
and active enrollment for the study occurred from 2012 to 2014; the study was registered
on ClinicalTrials.gov (identifier: NCT01450631).
Pregnant women undergoing cesarean delivery were approached for study participation
if they were ≥ 18 years of age with BMI ≥ 35 kg/m2 at the time of delivery. Participants provided written informed consent and were
enrolled either during their prenatal visits (for those undergoing planned cesarean
delivery) or when they presented to the Labor & Delivery Unit. Women with skin or
systemic infections, chorioamnionitis (defined by maternal fever + 1 clinical criteria),
critical illness, or high-risk for anesthesia (American Society of Anesthesiologists
[ASA] class P4, P5, or P6), were excluded from participation.
Immediately before cesarean delivery, all women received abdominal skin preparation
with a surgical solution (Chloraprep, CareFusion, Inc., San Diego, CA) and intravenous
cefazolin within 30 minutes before abdominal entry through a Pfannenstiel skin incision.
Delivery and abdominal closure were performed according to standard technique with
a combination of sharp and blunt dissection of the tissue planes. The peritoneum was
left open, and the subcutaneous adipose tissue was closed when deemed to be ≥ 2 cm
with chromic gut suture per institutional preference. Once the skin was reapproximated
with delayed absorbable sutures, the wound was confirmed as a “clean” (Centers for
Disease Control and Prevention [CDC] class 1 or 2) surgical incision, and all intraoperative
inclusion/exclusion criteria were met, the patient was randomized in a 1:1 fashion
to the ciNPT or SOC group. Study personnel obtained the next sequentially numbered
opaque randomization envelope, which contained the randomly assigned treatment group
for the participant. After being informed of the participant's assignment, trained
study personnel, who included the investigator/surgeon, subinvestigator/surgeon, or
research nurse, applied either the ciNPT or SOC dressing to the closed incision.
A sterile, “peel-and-place,” multilayer dressing (wicking fabric, reticulated foam,
and adhesive) was placed over the closed incision of patients in the ciNPT group.
The dressing's tubing was then attached to a compact, portable negative-pressure therapy
unit that delivered 125 mm Hg of continuous pressure to the dressing and removed exudates
into a disposable canister. Duration of ciNPT was ≥ 5 to ≤ 7 days, immediately following
surgery. For women in the SOC group, Steri-Strips (3M Health Care, ½ inch, St. Paul,
MN), sterile gauze, and Tegaderm (3M Health Care, transparent film dressings [nonpenetrable
barrier]) were applied to the closed surgical incision for at least 1 day and no longer
than 2 days. Women receiving at least 5 days of treatment in the ciNPT group or 1
day of treatment SOC group were classified as having received treatment per protocol.
All patients were discharged on postoperative day 3 or 4 in the absence of obstetrical,
medical, or wound complications requiring hospitalization for management. All patients
received standard wound care instructions before hospital discharge and teaching for
troubleshooting the ciNPT device. Subjects randomized to the ciNPT treatment group
returned for a study visit on day 6 (±1 day) to have the device removed and incision
assessed.
The primary endpoint of postoperative SSOs included unanticipated local inflammatory
response, prolonged drainage, fluid collection, dehiscence, and surgical site infection
(SSI). SSO was counted only once, even if a patient had more than one SSO during the
study period. The secondary endpoint of the study was the incidence of subjects with
surgical interventions, which included antimicrobials for SSI, surgical drainage of
the incision, surgical incision packing, adjunctive negative-pressure therapy, debridement,
or reoperation.
Although the postoperative examiner was privy to the treatment group, a standardized
wound scoring system was utilized to minimize bias. All participants were followed
up postoperatively for 42 ± 10 days via periodic incisional assessments (postoperative
days 1, 2, 6, 14, and 42) and monitored for adverse events. Surgical site assessments
were performed according to a standardized wound scoring system with a score between
1 and 5 assigned for each criterion: rubor, tumor, calor, and dolor. To account for
transient inflammatory responses, surgical site assessments were performed at least
1 hour following an intervention or dressing change.
Surgical site assessments included the supplementary outcomes of incisional pain scores
at rest and with pressure on the closed incision, as measured by the Wong–Baker Faces
Scale. A pain score greater than or equal to 2 was selected as the threshold for a
positive outcome, as the decision to seek narcotic analgesics are subjective and variable
with exception to a pain score of zero. Any occurrences of SSO were managed according
to institutional practice (e.g., antibiotics and re-exploration) as needed. Additional
data collected included: antibiotic use; suture line assessment; and medication use.
All narcotics and analgesic therapies (such as inpatient doses of acetaminophen, nonsteroidal
anti-inflammatory drugs [NSAID], and opioid narcotics [e.g., oxycodone, hydrocodone])
used during participants' postoperative hospital stays were obtained from the medication
record by the investigator after the study was completed. As narcotic use was not
standardized per study protocol, narcotic usage was converted to morphine equivalents.
The study was originally designed to compare the mean number of SSOs in each treatment
group. The mean and standard deviation of the number of SSOs for ciNPT and SOC were
assumed to be 1.0 (1.0) and 2.5 (2.5), respectively. The study would have 80% power
to detect this difference with 30 subjects enrolled in each group. Per protocol, an
interim analysis of the first 30 subjects was performed. Based on the interim analysis
of the primary outcome, it was determined that the SSO count was no longer relevant
and analysis would be done on the incidence rate. Based on the interim analysis results,
SSO rates of 6% ciNPT and 31% SOC, enrollment was increased to 46 participants in
each treatment group.
Statistical analysis was performed using SAS Version 9.2, (SAS Institute Inc., Cary,
NC). All statistical tests were two-sided, with type I error rate of 5%. Baseline
characteristics were defined before or immediately after cesarean delivery. All categorical
variables were summarized as frequencies and percentages. Continuous data were expressed
as mean, standard deviation, median, and range (minimum, maximum) unless otherwise
noted. Analyses of proportions, chi-square test, or Fisher's exact test were used
for all comparisons between the ciNPT and SOC groups. No adjustments were made to
p values for multiple comparisons. The Student's t-test was used for the subsequent analysis of analgesic use.
Results
Of the 101 women consented and assessed for study eligibility, 9 were considered screen
failures and were not included in the study. As shown in the CONSORT[13] patient flow diagram ([Fig. 1]), a total of 92 women were randomized to either the ciNPT or SOC groups (46 in each
group).
Fig. 1 CONSORT study population diagram.
The intent-to-treat (ITT) population (n = 92) included all randomized participants in the treatment arm to which they were
randomized. The per-protocol (PP) population (n = 82) consisted of 39 ciNPT and 43 SOC dressing participants who completed the study
within the required visit windows and had no protocol deviations. Final analysis of
study results for SSO included all 82 PP participants. In the seven women who did
not complete the study, no SSO events were noted before their discontinuation. It
is unknown if an SSO event occurred within 42 ± 10 days. Final analysis of study results
for participant-reported pain at the incision site was based on the ITT population,
which included all 92 randomized women (46 women per group).
Demographic and operative characteristics were calculated from the ITT population
and were similar between the treatment groups ([Table 1]). All women received preoperative antibiotics (cefazolin 2–4 g based on body weight)
within 30 minutes of the incision. None of the women underwent incisional drain placement,
anticoagulant therapy within 24 hours of cesarean delivery or cesarean hysterectomy.
Table 1
Demographic and incisional characteristics in the ciNPT, SOC, and overall treatment
groups calculated from the ITT population
|
ciNPT
(N = 46)
|
SOC
(N = 46)
|
Overall (ITT)
(N = 92)
|
|
Age (y), mean (SD)
|
30.4 (5.7)
|
29.7 (5)
|
30.0 (5.3)
|
|
BMI (kg/m2), mean (SD)
|
46.3 (7.3)
|
46.8 (5.6)
|
46.5 (6.5)
|
|
BMI (kg/m2), median (minimum, maximum)
|
46.4 (35.7, 60.8)
|
45.4 (38.9, 60.8)
|
45.8 (35.7, 60.8)
|
|
Race
|
|
American Indian, n (%)
|
0 (0%)
|
1 (2.2%)
|
1 (1.1%)
|
|
African American, n (%)
|
29 (63.0%)
|
35 (76.1%)
|
64 (69.6%)
|
|
Caucasian, n (%)
|
17 (37.0%)
|
10 (21.7%)
|
27 (29.3%)
|
|
Hispanic or Latino, n (%)
|
3 (6.5%)
|
2 (4.3%)
|
5 (5.4%)
|
|
Repeat or primary cesarean
|
|
Primary, n (%)
|
11 (23.9%)
|
15 (32.6%)
|
26 (28.3%)
|
|
Repeat, n (%)
|
35 (76.1%)
|
31 (67.4%)
|
66 (71.7%)
|
|
Diabetes, n (%)
|
8 (17.4%)
|
8 (17.4%)
|
16 (17.4%)
|
|
Gestational age (wk), mean (SD)
|
38.1 (2.0)
|
37.9 (2.0)
|
38.0 (2.0)
|
|
Incision length (cm)
|
16.3
|
16.3
|
16.3
|
|
Pfannenstiel incisions (percentile)
|
100.0
|
100.0
|
100.0
|
Abbreviations: ciNPT, closed-incision negative-pressure therapy; ITT, intent-to-treat;
SD, standard deviation; SOC, standard-of-care dressing.
Women who completed the study (PP, n = 82) had an overall SSO incidence of 11% ([Table 2]). Compared with women in the SOC group, those in the ciNPT group had a 63% relative
reduction in SSOs (7/43 [16.3%] vs. 2/39 [5.1%], p = 0.16) and fewer SSIs (4/43 [9.3%] vs. 1/39 [2.6%)], p = 0.36) ([Fig. 2]). Women in the SOC group were also more likely to have a dehiscence (5/43 [11.6%]
vs. 1/39 [2.6%], p = 0.20) and require surgical incisional intervention (6/43 [14%] vs. 1/39, 2.6%],
p = 0.11); however, these differences did not reach statistical significance.
Fig. 2 Wound complication rates. The percentage of participants in the ciNPT and SOC groups
who had any SSO and those who developed a SSI calculated from the per-protocol population
(n = 82). SSO, surgical site occurrence; SSI, surgical site infection; ciNPT, closed-incision
negative-pressure therapy; SOC, standard-of-care dressing.
Table 2
Breakdown of surgical site occurrences
|
ciNPT
(n = 39)
|
SOC
(n = 43)
|
p Value
|
|
Surgical site occurrence, any
|
2 (5.1%)
|
7 (16.3%)
|
0.16
|
|
Unanticipated local inflammatory response
|
0 (0%)
|
0 (0%)
|
|
|
Prolonged drainage
|
0 (0%)
|
0 (0%)
|
|
|
Fluid collection (seroma, hematoma, abscess)
|
1 (2.6%)
|
4 (9.3%)
|
0.36
|
|
Dehiscence
|
1 (2.6%)
|
5 (11.6%)
|
0.20
|
|
Surgical incision intervention, any
|
1 (2.6%)
|
6 (14.0%)
|
0.11
|
Abbreviations: ciNPT, closed-incision negative-pressure therapy; SOC, standard-of-care
dressing.
Overall participant-reported pain scores using the Wong–Baker Faces Scale with a value
of > 2 (any pain) postoperatively were evaluated between the treatment groups. In
the ITT population (n = 92), the ciNPT group, compared with the SOC group, had significant reductions in
both pain at rest (20/46 [43.5%] vs. 39/46 [84.8%], respectively; p < 0.001) ([Fig. 3]) and pain with pressure applied (25/46 [54.3%] vs. 42/46 [91.3%], p < 0.001) ([Fig. 4]).
Fig. 3 Participant-perceived pain scores at rest. Percentage of participants who reported
pain at rest with a value of > 2 (any pain) using the Wong–Baker Faces Scale, calculated
from the intention-to-treat population (n = 92). ciNPT, closed-incision negative-pressure therapy; SOC, standard-of-care dressing.
Fig. 4 Participant-perceived pain scores with pressure. Percentage of participants who reported
pain with pressure applied to a value of > 2 (any pain) using the Wong–Baker Faces
Scale, calculated from the intention-to-treat population (n = 92). ciNPT, closed-incision negative-pressure therapy; SOC, standard-of-care dressing.
Regarding postcesarean analgesia requirements, in the ciNPT group, compared with the
SOC group, total narcotic use was reduced by 30% (55.9 vs. 79.1) parenteral morphine
equivalents; p = 0.036). When comparing women in the ciNPT group to those in the SOC group, there
was no statistically significant difference for total acetaminophen use (6,882 vs.
6,924 mg; p = 0.47) and total NSAID use (1.65 vs. 1.51 maximum daily use equivalents; p = 0.87) ([Fig. 5]).
Fig. 5 Total analgesic use for hospital stay. Cumulative total inpatient use of acetaminophen,
NSAID, and narcotic opioid medications expressed as milligrams, maximum daily use
equivalents, and parenteral morphine mg equivalents, respectively. ciNPT, closed-incision
negative-pressure therapy; NSAID, nonsteroidal anti-inflammatory; SOC, standard-of-care
dressing.
Conclusion
Postcesarean wound complications, specifically in the extremely obese pregnant population,
remain a major issue in modern obstetrics. In this study of ciNPT versus SOC dressing
for incision management in an obese population undergoing cesarean delivery, we demonstrated
a trend toward reduction in incisional wound complications and a statistically significant
reduction in postoperative pain and narcotic use.
The study population was appropriate for the clinical question at hand, that is, women
at relatively high-risk for SSOs at baseline with a BMI > 35 kg/m2 at the time of cesarean delivery and without evidence of systemic infection. However,
after the planned interim analysis and sample size adjustment, the study remained
underpowered for the primary outcome due to an unexpected reduction in SSOs. Since
there were no institutional changes to cesarean technique or postoperative follow-up
care, factors aside from treatment may have affected this postinterim reduction in
SSO incidence. One possible factor was the lack of laboring women in our study after
an interim analysis. Other factors include the possibility of a “Hawthorne effect,”
in which the process of observation alone results in a reduction in the primary outcome
distinct from the intervention itself. Moreover, the study did not control for primary
versus repeat cesarean incisions though it is unlikely to be a significant factor
given that repeat cesarean has not been demonstrated to be an independent risk factor
for postcesarean wound morbidity previously. Although obesity is a major risk factor
for infection, it is likely that other cofactors such as labor or chorioamnionitis
play a significant role in the development of wound complications.
The trend toward a reduction of SSOs with ciNPT is clinically relevant, given that
SSIs were a component of the primary outcome and carry substantial costs to the individual
patient and health care system. A typical hospital readmission costs approximately
$6,600, for a postcesarean SSO.[14]
[2] The present study adds to the limited body of evidence regarding postoperative ciNPT
following cesarean. In a nonselective retrospective case–control study, Gibbs showed
no reduction in SSIs, when 103 patients with ciNPT were compared with 867 historical
controls after controlling for obesity and diabetes.[15] In contrast, a prospective case–control study by Swift et al showed a significant
70% reduction in wound complications among a high-risk group of 110 postcesarean women
treated with ciNPT versus 209 historical controls.[16] Similarly, Mark and colleagues had no postoperative infections in a group of 21
obese patients versus a 10% rate in 42 historical controls.[17] In our RCT, we also demonstrated a reduction in wound complications, which is consistent
with these recent studies in high-risk populations. The results of this study are
consistent with other data that suggest that ciNPT may reduce wound complications
in high-risk women. However, further studies are needed to determine whether the same
benefit applies to low-risk women undergoing cesarean.
Although potentially subject to bias, the significant reduction in postoperative incisional
pain, which was supported by a decrease in narcotic use among women in the ciNPT group,
has significant implications for postpartum and postoperative pain management. Prior
studies of postcesarean analgesia techniques (e.g., patient-controlled analgesia)
have noted that ineffective pain relief may exacerbate the risk for thromboembolism
via immobility as well as reduce mother–infant bonding and breastfeeding, which are
complications of particular clinical relevance in an obese obstetrical population.[18]
[19] More recently, studies evaluating medical and psychosocial risk factors in patients
with opioid dependence have identified the antecedent use of postoperative opioid
analgesia as a potential “gateway” to dependence.[18] If further research confirms or expands on our finding of a significant reduction
in postoperative pain and total opioid narcotic intake, the use of ciNPT may be considered
for its ancillary benefits in postcesarean women.
The obesity epidemic and its management are, and will likely continue to be, a central
focus of current obstetric care for the foreseeable future. Treatment strategies such
as ciNPT are needed to reduce cost and associated morbidity of wound complications.
We acknowledge the need for further RCTs with adequate power to examine the impact
of ciNPT in risk-diverse obstetric populations. It is imperative that such studies
account for additional benefits beyond wound complications, such as postoperative
pain management, narcotic utilization, and patient satisfaction.